November 20, 2017 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer

Basel, 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA)... Read more

November 20, 2017 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer

Basel, 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA)... Read more

October 31, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Phase II Clinical Trial Data Establishes Effectiveness of using a Child's Own Cord Blood to Treat Cerebral Palsy

Key Discoveries in the Therapeutic Application of Cord Blood: Improvement of Motor Function in Children with Cerebral Palsy WALTHAM, Mass.–(BUSINESS WIRE)– Research published in Stem Cells Translational Medicine shows encouraging developments related to using a child’s own cord blood to treat childhood brain injury known as cerebral palsy (CP). The research from a Phase II... Read more

October 25, 2017 Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Shimadzu Scientific Instruments, Cure Pharmaceutical Corp and CK Sciences Form a Strategic Alliance for R&D of Pharmaceutical Cannabis Products

Columbia, MD (October 25, 2017) — Shimadzu Scientific Instruments, the leading provider of cannabis testing instruments, announces it has signed a Memorandum of Understanding (MOU) with Cure Pharmaceutical Corp and CK Sciences. This collaborative agreement will focus on researching and developing safer pharmaceutical cannabis-based products and moving these products through clinical trials using FDA guidelines.... Read more

October 24, 2017 Bio/Pharma/CRO Lab Top-10

Tufts Center for Drug Development Study Quantifies Multimillion-Dollar Benefits of Using Single-Source Pharma Drug Development and Manufacturing Model

Tufts Center for Drug Development Study Quantifies Multimillion-Dollar Benefits of Using Single-Source Pharma Drug Development and Manufacturing Model DURHAM, N.C., Oct. 24, 2017 /PRNewswire/ — A newly released modeling study conducted by The Tufts Center for the Study of Drug Development (CSDD) finds that sponsors who employ single-source outsourcing partners, versus a multivendor development and... Read more

October 17, 2017 Acad, Gov/Utilities Bio/Pharma/CRO Industrial

VWR and Scientist.com Collaborate to Create an End-to-End Online Research Solution

RADNOR, Pa., Oct. 17, 2017 /PRNewswire/ — VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, today announced its collaborating with Scientist.com, the leading global online marketplace for research services. VWR customers in the U.S. can now purchase thousands of custom products and research services through... Read more

October 12, 2017 Bio/Pharma/CRO Cell Analysis Tools PR/Corporate

BioTime, Inc. Announces Proposed Public Offering of Common Stock

ALAMEDA, Calif.–(BUSINESS WIRE)–Oct. 12, 2017– BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. BioTime intends to grant the underwriters a 30-day option to purchase up to... Read more

October 12, 2017 Bio/Pharma/CRO

Avantor Opens New Korea Life Sciences Research and Applications Facility

New Avantor Korea Laboratory is focused on optimizing biopharmaceutical purification processes for customers in the rapidly expanding life sciences industry in South Korea Located near local pharmaceutical and biopharmaceutical research and production customers, the Avantor Korea Lab offers both in-house and field service applications development support. Center Valley, PA (USA) – October 12, 2017 –... Read more